Clinical Trials Logo

Prostate Cancer clinical trials

View clinical trials related to Prostate Cancer.

Filter by:
  • Withdrawn  
  • Page 1 ·  Next »

NCT ID: NCT04486846 Withdrawn - Prostate Cancer Clinical Trials

Electronic Post-Treatment Surveillance Program for Prostate Cancer Survivors (eHealth)

Start date: June 2021
Phase: N/A
Study type: Interventional

The purpose of this single institution pilot study is to determine the feasibility of implementing an eHealth prostate cancer surveillance program through the eVisit electronic medical record patient portal. The investigators will assess patient compliance and satisfaction with eVisit follow up care in lieu of in person clinic visits.

NCT ID: NCT04403568 Withdrawn - Prostate Cancer Clinical Trials

Testing the Synergism of Phytonutrients, Curcumin and Ursolic Acid, to Target Molecular Pathways in the Prostate

Start date: October 2021
Phase: Early Phase 1
Study type: Interventional

A proof of concept clinical trial to assess the synergism of curcumin (CURC) and ursolic acid (UA). Before further testing within formal cancer clinical trials, we must (1) evaluate the bioavailability and safety, (2) confirm the presence of metabolites in the target organ, and (3) validate the appropriate mechanism of effect

NCT ID: NCT04296578 Withdrawn - Prostate Cancer Clinical Trials

Study Evaluating Sodium Selenite in Combination With Abiraterone in Castrate Resistant Prostate Cancer Progressing on Abiraterone

Start date: October 2020
Phase: Phase 1
Study type: Interventional

The purpose of this study is to access the safety of combining sodium selenite with abiraterone and to see what doses of sodium selenite can be safely combined with abiraterone in treating castration resistant prostate cancer.

NCT ID: NCT04272645 Withdrawn - Prostate Cancer Clinical Trials

Abemaciclib With or Without Atezolizumab in Metastatic Castration Resistant Prostate Cancer

Start date: October 2020
Phase: Phase 2
Study type: Interventional

This research is studying two experimental drugs, abemaciclib and atezolizumab, alone and in combination with each other, to learn about the safety and effectiveness of these treatments and their side effects. This is an investigational study treatment for adult men with metastatic castrate resistant prostate cancer (mCRPC) who have progressive disease despite previous treatment with androgen deprivation therapy (ADT). One group of men (men without a genetic mutation called "CDK12 loss") will receive abemaciclib therapy alone. Two other groups of men (men with CDK12 loss in one group and men without CDK12 loss in the other) will receive the combination of abemaciclib and atezolizumab. Another group of men with CDK12 loss will receive atezolizumab therapy alone.

NCT ID: NCT04027270 Withdrawn - Prostate Cancer Clinical Trials

Pelvic Health and Physical Therapy to Improve Lives of Prostate Cancer Patients Undergoing Prostatectomy

Start date: January 2021
Phase: N/A
Study type: Interventional

Patients will be randomized into standard of care or receiving pre and post operative physical therapy intervention following prostatectomy. Outcome measures will be gathered to assess impact of physical therapy on function and quality of life.

NCT ID: NCT03817216 Withdrawn - Prostate Cancer Clinical Trials

Prostatic Urethral Lift (PUL) Pre-/Post-Radiation Treatment for Prostate Cancer

Start date: December 2019
Phase: N/A
Study type: Interventional

The purpose of this study is to test the use of the Prostatic Urethral Lift (PUL), Urolift®, in prostate cancer (Pca) participants seeking or undergoing radiotherapy for relief of urinary obstructive symptoms.

NCT ID: NCT03748719 Withdrawn - Prostate Cancer Clinical Trials

Single Arm Trial of Preoperative Stereotactic Body Radiation Therapy (SBRT) for T3a or Gleason Grade Group 4 Prostate Cancer

Start date: November 19, 2018
Phase: N/A
Study type: Interventional

This study involves Stereotactic Body Radiation Therapy (SBRT) followed by prostatectomy (removal of the prostate). SBRT is a relatively new radiation technique in which a few doses of radiation are delivered to small, well-defined tumors. It has been used effectively in other cancers like lung and liver. The radiation will be given for only 5 days. The purpose of this study is to compare the effects, good and/or bad, of different doses of SBRT given before prostatectomy.

NCT ID: NCT03589781 Withdrawn - Prostate Cancer Clinical Trials

Investigating the Effects of Mikei® Red Reishi Essence EX on the Immune System of Prostate Cancer Patients and Patients With Non-cancerous Conditions of the Prostate

Start date: November 5, 2020
Phase: N/A
Study type: Interventional

The primary objective of this study is to determine the effects of Mikei® Red Reishi Essence EX extract powder on the immune function of prostate cancer patients and patients with non-cancerous conditions of the prostate.

NCT ID: NCT03495479 Withdrawn - Prostate Cancer Clinical Trials

Aneustat Treatment of Localized Prostate Cancer Under Active Surveillance

CAMPAS
Start date: January 2025
Phase:
Study type: Observational

Assessment of the effects of OMN54 (Aneustat) in a population of men with indolent prostate cancer who are otherwise healthy and free of significant co-morbidities and have chosen active surveillance for disease management. The investigators will assess how OMN54 affects PSA, overall tumor burden in addition to any changes in urinary flow. Other biomarkers will be tested to follow disease evolution.

NCT ID: NCT03488810 Withdrawn - Prostate Cancer Clinical Trials

Apalutamide With Radiotherapy and Androgen Deprivation Therapy in Prostate Cancer

ARN-509
Start date: March 10, 2020
Phase: Phase 3
Study type: Interventional

The main objective of the trial to determine if the combination of apalutamide with 6 months of androgen deprivation therapy by LHRH agonists in patients with intermediate and limited high-risk, localized prostate cancer receiving primary radiation therapy (RT) results in an improvement of disease-free survival (DFS) evaluated by the treating physician, in comparison to the combination of radiation and androgen deprivation therapy without the addition of apalutamide.